4, 4′‐Dimethylaminorex ("4, 4′‐DMAR"; "Serotoni") misuse: A Web‐based study. (May 2017)

• Record Type: Journal Article
• Authors: Loi, Barbara; Zloh, Mire; De Luca, Maria Antonietta; Pintori, Nicholas; Corkery, John; Schifano, Fabrizio
• Is Part Of: Human psychopharmacology. Volume 32:Number 3(2017:Apr.)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-05
• Subjects: 4, 4′‐DMAR -- aminorex derivatives -- novel psychoactive substances -- online fora -- psychonauts -- stimulants; Psychopharmacology -- Periodicals; Psychotropic drugs -- Periodicals; Psychopharmacology -- Periodicals; Psychotropic Drugs -- pharmacology -- Periodicals; 615.78
• DOI: 10.1002/hup.2575
• Languages: English
• ISSNs: 0885-6222

Abstract

Abstract: Background: 4, 4′‐DMAR (4, 4′‐dimethylaminorex; "Serotoni") is a potent stimulant drug that has recently been associated with a number of fatalities in Europe. Over the last few years, online communities have emerged as important resources for disseminating levels of technical knowledge on novel psychoactive substances. Objective: Analysing the information provided by the fora communities on 4, 4′‐DMAR use, additionally critical reviewing the available evidence‐based literature on this topic. Methods: Different website drug fora were identified. A critical review of the existing evidence‐based literature was undertaken. Individuation and analysis of qualitative data from the identified website fora were performed. Results: The combined search results identified six website fora from which a range of qualitative data on recurring themes was collected. These themes included routes of administration and doses; desired effects; adverse effects; comparison with other drugs; association with other drugs; medications self‐administered to reverse 4, 4′‐DMAR action; overall impression; and provision of harm‐reduction advice. Conclusions: Although being characterized by a number of methodological limitations, the social networks' Web monitoring approach (netnography) may be helpful to better understand some of the clinical and psychopharmacological issues pertaining to a range of novel psychoactive substances, including 4, 4′‐DMAR, for which only extremely little, if any, scientific knowledge is available.